Muniba Faiza

Muniba Faiza

Auto-generated profile, based on publicly available information

Muniba Faiza

Department of Biology, Nazarbayev University, Qabanbay Batyr Avenue, Nur-Sultan, Kazakhstan

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in LWT
Verified
Journal Article
Closed access
DLDaoming Li
Daoming Li
XZXiaorong Zhong
Xiaorong Zhong
MFMuniba Faiza
Muniba Faiza
WWWeifei Wang
Weifei Wang
WLWeishuai Lian
Weishuai Lian
YWYonghua Wang
Yonghua Wang

1 March 2025 in Infectious Disorders - Drug Targets
Verified
Journal Article
Closed access
RKRajnish Kumar
Rajnish Kumar
SGSamarth Gupta
Samarth Gupta
SASujata Adhana
Sujata Adhana
AKAnoushka Khanna
Anoushka Khanna
SSSibasis Sahoo
Sibasis Sahoo
UCUma Chaudhry
Uma Chaudhry
Background: Shiga Toxin-Producing Escherichia coli (E. coli O157:H7), capable of causing serious food-borne illnesses, is extensively studied and is known to be transmitted through animal reservoirs or person-to-person contact, leading to severe disease outbreaks. The emergence of antibiotic resistance in these strains, coupled with increased adverse effects of existing therapeutics, underscores the urgent need for alternative therapeutic strategies. Objective: This study aims to evaluate Glutamate Racemase (MurI protein) of the food-path-ogenic E. coli O157:H7 (EC MurI) as a novel drug target. Furthermore, the study seeks to identify new compounds with potential inhibitory effects against this protein. Methods: Using computational tools, the study identified inhibitor binding sites on EC MurI and identified relevant inhibitors capable of binding to these sites. Molecular docking tech-niques were employed to assess potential hits, and selected compounds were further analyzed for their structural activity and binding affinity to the protein. Results: The results of the study revealed that Frigocyclinone and Deslanoside, exhibited the best binding affinity with EC-MurI. Subsequent molecular dynamic (MD) simulations of the selected complexes indicated that both compounds were stable. This suggests that Frigocy-clinone and Deslanoside have the potential to serve as potent inhibitors of EC-MurI. Conclusion: In summary, this study highlights the urgent need for alternative therapies against food-pathogenic E. coli, focusing on E. coli O157:H7. Evaluation of Glutamate Race-mase as a drug target identified Frigocyclinone and Deslanoside as promising inhibitors. MD simulations indicated their stability, suggesting their potential as lead molecules for further research and treatment development.

14 June 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
MFMuniba Faiza
Muniba Faiza
TATariq Abdullah
Tariq Abdullah
JCJose Franklin Calderon-Tantalean
Jose Franklin Calderon-Tantalean
MUManish Ravindranath Upadhyay
Manish Ravindranath Upadhyay
AAAbdelrahman H. Abdelmoneim
Abdelrahman H. Abdelmoneim
UCUma Chaudhry
Uma Chaudhry
The recent outbreak of severe acute respiratory syndrome (SARS) coronavirus (CoV)-2 (SARS-CoV-2) causing coronavirus disease (covid19) has posed a great threat to human health. Previous outbreaks of SARS-CoV and Middle East respiratory Syndrome CoV (MERS-CoV) from the same CoV family had posed similar threat to human health and economic growth. To date, not even a single drug specific to any of these CoVs has been developed nor any anti-viral vaccine is available for the treatment of diseases caused by CoVs. Subunits present in spike glycoproteins of SARS-CoV and SARS-CoV-2 are involved in binding to human ACE2 Receptor which is the primary method of viral invasion. As it has been observed in the previous studies that there are very minor differences in the spike glycoproteins of SARS-CoV and SARS-CoV-2. SARS-CoV-2 has an additional furin cleavage site that makes it different from SARS-CoV (Walls et al., 2020). In this study, we have analyzed spike glycoproteins of SARS-CoV-2 and SARS-CoV phylogenetically and subjected them to selection pressure analysis. Selection pressure analysis has revealed some important sites in SARS-CoV-2 and SARS-CoV spike glycoproteins that might be involved in their pathogenicity. Further, we have developed a potential multi-epitope vaccine candidate against SARS-CoV-2 by analyzing its interactions with HLA-B*15:03 subtype. This vaccine consists of multiple T-helper (TH) cells, B-cells, and Cytotoxic T-cells (CTL) epitopes joined by linkers and an adjuvant to increase its immunogenicity. Conservation of selected epitopes in SARS, MERS, and human hosts, suggests that the designed vaccine could provide cross-protection. The vaccine is designed in silico by following a reverse vaccinology method acknowledging its antigenicity, immunogenicity, toxicity, and allergenicity. The vaccine candidate that we have designed as a result of this work shows promising result indicating its potential capability of simulating an immune response.